Guest post: Time to bring human genome sequencing into the clinic by Lyon,  Gholson J.
Guest post: Time to bring human genome sequencing into the clinic « Genomes Unzipped
file:///C|/Users/mcovey/Documents/Lyon%20Archive/guest-post-time-to-bring-human-genome-sequencing-into-the-clinic.htm[2/4/2013 9:57:32 AM]
Home About Project Members Resources Data/Code Browser Subscribe Contact  
« Review of the Lumigenix “Comprehensive” personal
genome service
All genomes are dysfunctional: broken genes in healthy
individuals »
Photo of Max, who died
aged four months from
Ogden syndrome. Posted
with permission from his
family.
Gholson Lyon is a physician-scientist currently working at the Utah Foundation for Biomedical
Research and the Center for Applied Genomics at Children’s Hospital of Philadelphia. He will
be starting as an assistant professor in human genetics at Cold Spring Harbor Laboratory
next month. I asked him to write this guest post to provide some personal context to his
thought-provoking commentary in Nature (subscription required) on returning genetic
findings to research subjects. [DM]
I have just published in Nature a commentary discussing the
need to bring exome and genome sequencing into the clinical
arena, so that these data are generated with the same
rigorous clinical standards as for any other clinical test. This
way, we can then easily return at least medically actionable
results to research participants. In this day and age of
consumer and patient empowerment, I can also see eventually
returning all data, including the raw data, to any interested
participants, as this can then promote crowd-sourcing for
data analysis, with research participants controlling and
promoting the relative privacy of and analysis of their own
data.
As I described in my commentary, my thinking on this matter
was prompted mainly by Max  (see picture) and his family.
The obituary for Max can be found here, and that of his
cousin, Sutter, here. We described their condition here, and
we named this new disease Ogden Syndrome in honor of where the first family lives. I am
now trying to think about and discuss the human aspects of and lessons from this story. My
thinking has also been influenced somewhat by the late James Neel, who wrote a very
thought-provoking book called Physician to the Gene Pool.
To me, it was deeply disconcerting that I could not officially return any results to this family
(or to another family in a different project discussed here) even when the papers describing
the genetic basis of their disease were published, as this was considered “research” and was
not performed in a clinically appropriate (CLIA-certified) manner. This was all the more
painful when one of the sisters in the Ogden family became pregnant and asked me what I
knew. I cannot predict whether it would have helped or hurt this woman to learn during her
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pregnancy that she was indeed a carrier of the mutation, with the associated 50% risk of her
baby boy having the disease. I also do not know if she would have undergone any genetic
testing via amniocentesis of the fetus prior to birth (with the associated ~1% risk of
miscarriage from the procedure), nor do I know what decisions she might have made prior to
the birth even if she had undergone such testing. All in all, it was certainly an ethical and
moral dilemma for me not to be able to return the research result to her, given that the
results were not obtained in a CLIA-certified manner. It is still an issue, as there are even now
financial and systematic barriers for getting all women in the family tested with a CLIA-
certified gene test for NAA10 (which was developed over a six month period by ARUP
Laboratories). It would have been so much better if we had just done the entire
sequencing up front in a CLIA-certified manner.
It is therefore my opinion that the current flood of human sequencing data is not being
optimally generated, given that there is no regulation requiring the initial sequencing of each
human to be performed in a clinical-grade manner, thus making it very difficult and unwise
for anyone to return any research information to research participants. This is due to the fact
that clinicians must “first, do no harm”, so returning less than clinical grade sequencing
results to patients can potentially cause such harm, as noted above. Therefore, the natural
corollary to this argument (to me at least) is that initial sequencing of human exomes and
genomes should be performed in a CLIA-certified (or other clinical-grade) manner up front,
so that the data can be returned to research participants and/or linked to their medical
record. That way, as knowledge expands over the next few decades, we can constantly go
back and re-analyze the genomes and update research participants on new unrelated
findings, in the context of their biochemical individuality. Of course, one can always re-
sequence using newer technologies and/or confirm any important results on a new DNA
sample from each person, but there will no longer have to be rigorous development of a
specific CLIA-certified gene test for each mutation, given that the exomes and genomes were
sequenced up-front in a clinically proper manner.
What are the benefits?
The medical system in America is currently geared and financially rewarded to treat specific
issues that people have when they are ill, whereas there are relatively few incentives in the
system for counseling (genetic and otherwise) and keeping people healthy. This needs to
change. A federal guideline mandating that the first exomes and genomes on each human be
performed in a CLIA-certified or otherwise clinically appropriate environment could save
substantial money in the long run, for many reasons, in my opinion, including in the area of
preventive medicine. This of course includes beefing up the number of genetic counselors
initially, but there is accumulating evidence that at least some people take corrective actions
(some of which can be life-saving) when they learn of genetic predispositions. Also,
preimplantation diagnosis and other preventive efforts may benefit readily from the increased
carrier screening that will accompany the clinical sequencing of humans.
Problems with the current system
Some researchers have suggested that the “easy” thing would be to “simply” re-sequence the
research samples for each mutation of importance in an already CLIA-certified lab. However,
this overlooks many things, including 1) not obtaining the blood/saliva or isolating, storing
and tracking the DNA in any sort of specified and reproducible manner, 2) not developing an
official CLIA-certified Sanger-sequencing test for this particular gene, and 3) not interpreting
the Sanger sequencing in any sort of CLIA-certified manner. It is not enough to just place a
sequencing machine in a “CLIA-certified lab” and then simply declare that all DNA, no matter
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how that DNA was obtained, stored, or tracked, nor how the sequencing data were analyzed,
will suddenly now yield “CLIA-certified” results, deliverable back to research participants.
What about the real risks of sample mix-up and incorrect results? In addition, are researchers
really going to take the time to develop CLIA-certified tests for each and every one of the
possible medically-actionable mutations that they uncover now?
Conclusion
Even though it is very likely that whole genome sequencing will become a routine part of
clinical care in 10-20 years, it is far from certain what the path and process toward this goal
will be. In science, much as in public policy, there is sometimes Brownian motion, whereby
there are many small steps forward and backward, with many people losing perspective on
the overall progress being made. Thirty years ago, very few people would have predicted that
in vitro fertilization and test tube babies would become a routine part of medicine, even
garnering a Nobel Prize for one of the champions of this technology. Furthermore, targeted
carrier screening and pre-implantation genetic diagnosis is also becoming a routine part of
medical care, particularly in some communities with an excess burden of recessive genetic
diseases. So, the real question is: where we will be in two years? And in five years? The
current sequencing will certainly lead to many scientific papers and discoveries, but the
question is whether any of this sequencing, genetic discoveries, or unrelated findings will
actually directly benefit anytime soon the actual families who took the time to donate their
blood and other tissue samples? Will results, including unrelated findings, be returned to
these families so that they can take preventive measures? Will the genomic data be returned
directly to research participants so that they control the privacy of and access to their own
genomic data? If so, how will this be done to minimize error and misinformation?
Hopefully, one day soon, each person will possess a copy of their own clinically certified
genome, and they will then have the option to link their genome to their medical record
and/or to provide their own genome data to other researchers. Indeed, some people could
even contribute to the analysis as citizen scientists, akin to what is described in the new book
Reinventing Discovery: The New Era of Networked Science by Michael Nielsen. Many
researchers and interested participants can then together analyze the genome of each person
repeatedly, as our collective knowledge expands. The consent process could also follow the
model being proposed by the Sage Bionetworks Common Genomic Research Project,
including a version of “portable legal consent“.  Right now is hopefully a revolutionary time in
medicine, as discussed by Eric Topol in his new book The Creative Destruction of Medicine, so
we should seriously consider doing the right thing now, before we have gone down this
current path far too long.
Afterword
I am struck by the following quote in a recent Nature editorial:
What kind of work deemed as accepted today will be denounced by future
generations? The question is one that all researchers should bear in mind, because
history may judge them more harshly than their peers do.
Currently, it is the wild West for human genome sequencing. Many researchers are
sequencing as many exomes and genomes as possible, using a range of methods. However, I
am struck by the question of whether we are really thinking through the ethics of this. In the
1940’s, there was a huge rush to find a cure for syphilis and other venereal diseases, and this
led many prominent researchers to conduct experiments on humans that we now look back
on as being morally repugnant. Are we repeating the same mistake when we sequence live
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humans in research environments in which we are not able (or perhaps willing) to inform and
counsel these people concerning potentially very deleterious mutations in their genomes? Are
we keeping these people “in the dark” and thereby taking away from them the chance to take
preventive measures for highly penetrant mutations running in their families, i.e. their “clan
genomics”?
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Neil
17/02/2012 at 11:14
The title of your Nature piece is:
Personalized medicine: Bring clinical standards to human-genetics research
Whereas the title of this piece is:
Time to bring human genome sequencing into the clinic
These are markedly different. It is possible to agree with the second, but not the first.
People doing clinical-grade genetics are kinda busy. Do they want to waste their time on the
worried well(ish) when there are desperately serious cases like the ones you refer to, to be
diagnosed?
But where are the findings that clinical genetics relies on going to come from, if research-grade
research stops?
We have to assume that the price of doing clinical-grade research is much, much higher than
doing research-grade research: is the subsequent loss of research a price worth paying? For
example, I would anticipate that none of the samples used in any of the WTCCC projects meet
the tracking and storage requirements that can absolutely guarantee results come from the
correct subject. We do our best, but know that is not the same thing. Are we therefore to stop
large-scale genetics research, for fear we find something that places us in a moral dilemma?
Note – that is not a rhetorical question, but genuinely an option facing some research groups.
Perhaps we should ask the research subjects what they want? i.e. are you taking part in this
research in order to get a diagnosis? If so let’s do clinical grade research – or refer you
somewhere that does it. If not, are you prepared to take part in genetic studies knowing that we
will not feed back information to you; or will only feed back information if we know it to be life-
threatening, and with the caveat that you will need to be re-tested by something more clinical
grade?
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Ruslan Dorfman
17/02/2012 at 14:21
That is quite sad that people so hang up on the concept of “research” grade finding vs “CLIA-
certified” findings. If you are not sure in the quality of your genetic research so why bother
publishing it? On other side if you really found something disturbing like the case described in
the paper it is researchers moral and ethical obligation to consult with genetic counselors and
facilitate independent validation in another laboratory even it if is not CLIA-certified. Could could
have saved a lot of pain for these families by taking a bit more personal responsibility and being
more proactive. I understand the reluctance in the view of legal issues, but every University and
Hospital has an able legal team that could be consulted with in a due time.
Some people forget that the primary goal of research is to help people and not publish paper
and wait when someone else will pick the tab to implement research findings.
Gholson Lyon
17/02/2012 at 20:26
I feel that I should respond to the above comments, although I will be addressing such issues in
future talks and commentaries as well.
I would argue that I was MUCH more proactive than most researchers in this context, because I
actually met the family, got the CLIA-certified test developed, am working to get them tested and
counseled, etc…. There are many issues involved, which I have tried to begin addressing in the
commentary and this posting, mainly to get more discussion going on this subject. Also, please
just read the Retraction Watch website to discover how much “research” is of poor-quality, for
many reasons. Also, I don’t remotely agree with you about “saved a lot of pain for these families
by taking a bit more personal responsibility”, as I would challenge you or anyone else to indicate
to me what more I could have done in this extremely challenging situation? I am trying to help
researchers to become more aware of these issues, because you can avoid all this by doing the
sequencing up front in a CLIA-certified or clinical-grade manner, or alternatively you could be
VERY explicit in your consent documents about NON-return of ANY results and/or complete de-
identification of samples (making this completely 100% research only), but of course losing out
on the ability to go back to these families for future information. I say this latter thing because it
is a two-way street, because if one goes back to families or medical records for updated
information, this means you then should take responsibility for conveying important clinical-
grade findings back to these families.
I agree that one alternative is that the informed consent documents could be very explicit
regarding non-return of ANY research results, including explicit example statements such as “If
we find a Huntington’s disease mutation or highly penetrant breast cancer mutation, we will NOT
tell you about this, as this is research only and you will derive ZERO benefits from this research”,
and there should be no grey zone in between, lest we mislead participants into thinking that we
actually plan to help or counsel them in any way about their genetic findings. Or, the samples
can be completely deidentifed with ZERO intent for re-identification, which should also be made
very clear to anyone asked to participate in such a study. However, if there is the chance for re-
identification by the researchers, then return of results must be discussed explicitly and very
concretely with participants, in terms of return or NON-return of anything. Otherwise, one enters
into this slippery slope of how to return results reliably and appropriately if the sequencing was
not done up front in a clinical-grade manner.
I have inserted below some typical language that I found in one IRB-approved informed consent
protocol for collecting genomic DNA for research, so that I can deconstruct the implications of
this language with the reader.
Example language:
1) “It is possible that we will uncover disturbing information about you or your family during this
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research. For example, information about paternity or adoption might be discovered. We will not
reveal this information unless it has direct medical significance for your family.”
2) “BENEFITS. We hope that this study will help us better understand the condition that affects
you, however there may not be any direct benefit to you. If we find anything of medical
significance to you or your family during this study, we will inform you in writing and provide you
with an opportunity to speak with a medical geneticist or genetic counselor to explain the
results.”
3) “NEW INFORMATION. If we learn something that might affect whether you want to be in the
study, we will tell you. We plan to report the results of this study to you or your family. We will
try to keep you informed about progress of the research.”
Such language in an informed consent is very well-intentioned, but also very misleading to the
participant, as it is not clear to me that this has been well-thought out in terms of how research
results can be returned in any sort of meaningful or systematic way, given that they are not
obtained in any sort of clinically regulated manner, i.e. CLIA-certified in America. Researchers
might face major risks of lawsuits if they return incorrect or misleading results to research
participants, plus giving research-grade results back to people is basically practicing bad
medicine without a license, which is why I am asking that the sequencing be performed in such a
manner as to involve clinicians. We have agencies and policies like FDA, Medicare, and CLIA to
ensure that test results and other things offered to people meet certain high standards;
otherwise, there is substantial risk of misinformation and misguided “counseling”.
Hisham (biohisham)
18/02/2012 at 09:34
In addition, are researchers really going to take the time to develop CLIA-certified tests for each
and every one of the possible medically-actionable mutations that they uncover now? [/quote]
Actually, why not have standards, the data brought to the clinic has to be free from these
ambiguities that we have come to tolerate in sequencing what with tweaking the data and what
with increasing the coverage or read depth, a clinical diagnosis is not like a ROC curve where
there are grey areas, it has to be a clear cut diagnosed versus non-diagnosed with enough
evidence to tell the patient and deliver an impact on their treatment options.
In sequencing, the problems start from the platform, go on to the analysis, culminate in the
assembly of the genomes afterwards and some of these errors are inherent in the system and
others are batch-driven so clinicians can’t really tolerate that fuzziness and of course it is so
justifiable.
Back to what I quote from your article, ‘TIME’, is it ‘time’ or ‘willingness’, or maybe a combination
of both that may influence the demotivation that you felt? Many of the breakthroughs were made
because an issue affected the inventor directly (probably his offspring suffered a genetic
disability) and they were keen into getting to the bottom of it, e.g is the IonTorrent story. So I
highly doubt that ‘time’ is the matter here, bioinformaiticians and folks in the NGS arena are
probably too much burrowed into the joy they experience in their own field rather than seeing
areas of applications such as the clinical field for them to shape-up, I am a bioinformatician
myself however,I will side with the notion that it comes from humans – the data that we are
fascinated with- and we have to bring it back to them in the form of a credible assessment of
their genetic makeup.
Clinicians like Stephen Kingsmore are engaged into developing a pipleine for finding disease
causing variants and they wanna standardize the analysis process in a form befitting the clinical
requirements.
Neil
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18/02/2012 at 11:30
Researchers might face major risks of lawsuits if they return incorrect or misleading
results to research participants, plus giving research-grade results back to people is
basically practicing bad medicine without a license, which is why I am asking that
the sequencing be performed in such a manner as to involve clinicians.
Which sequencing? All sequencing?
The next post on this site goes into great detail into how healthy people harbour major loss-of-
function genetic variants. If someone has, or is suspected to have, a rare genetic disorder, these
are just the things we would look for and want to feed back. Without that motivation, there is no
reason to think these variants are majorly harmful to the individual concerned. The first scenario
needs a clinician and genetic counselling, the latter doesn’t.
Gholson Lyon
18/02/2012 at 13:56
I agree that none of the major sequencing projects currently have anything in place to adequately
track the samples and data to any particular individual, at least not to the high standards
required of clinical tests. This is exactly the problem. As I alluded to above and in my
commentary, I am asking that the INITIAL exome and whole genome sequencing of each human
should be performed in a clinical-grade manner, so that at least medically actionable results can
be returned to families, in which their “clan genomics” are known, i.e. there is evidence that
these mutations are causative for disease in the context of their genomes and environment.
Ideally, I would like to have all clinical-grade genomic data returned to participants so that they
can decide whether to link the data to their medical record for future analysis and/or to release
their data to other researchers, thus empowering and engaging the participants in a meaningful
way. Researchers can then sequence and re-sequence the DNA as much as they like in a research
setting, with explicit consent from participants that no such information will be returned, but I
am asking researchers and policy-makers to consider that it should be necessary and required to
perform at least clinical-grade sequencing up front for the first exomes or genomes on any live
humans participating in human genetics research, so that results can be easily returned with
appropriate counseling. In America, return of results requires CLIA certification; in other places it
would require approval from other bodies; and in some settings (e.g. some developing countries)
where the regulatory environment is unclear, it would simply require improving the standard of
sample collection testing to reduce the incidence of sample swaps and other false results.
At the moment, the only place to my knowledge in America offering CLIA-certified whole genome
sequencing is at Illumina, but Complete Genomics is applying now for CLIA-certification for their
whole genome sequencing, plus several companies, including 23andMe, are now offering CLIA-
certified exome sequencing. To the best of my knowledge, in the case of Illumina, the process
involves drawing the blood in a barcoded tube sent to the ordering physician by Illumina,
followed by shipping the blood to Illumina for CLIA-certified DNA extraction and sequencing,
which dramatically minimizes any possibility for sample mix-up. Their bioinformatics pipeline
also originates from the CLIA-certified environment, and their list of variant calls is necessarily
stringent to lower the number of false positives. From a research and discovery perspective, this
might mean missing some possible variants due to certain regions of the genome not having
adequate coverage for a reliable call, but the raw data are available and can always be re-
analyzed in a research setting and/or with improving CLIA-certified bioinformatics pipelines.
There is a certain economy of scale and reliability (think Amazon) with centralizing CLIA-certified
whole genome sequencing with companies such as Illumina and Complete Genomics, but I
suspect that other companies and institutions will nonetheless want to offer this service
themselves too. So, it is simply a matter of establishing minimal guidelines that must be met in
order for such places to generate CLIA-certified exomes and whole genomes. The bottom line is
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that CLIA-certified sequencing is already available now, and it is time to embrace this in a clinical
setting, so that the fruits of the human genome project can finally start to help families and
patients on a broader level.
Ülo
22/02/2012 at 20:36
If I understand correctly, ogden syndrome is a recessive x-linked disease for which the authors
knew that the maternal grandmother of the male fetus was a carrier. If the mother knows that
she is a carrier also, her probability of giving birth to a sick boy is 50%. On the other hand, if the
mother does not have this information her subjective probability is 25% and if the mother knows
for sure that she is not a carrier the probability approaches zero.
The expert choose to withhold information from the mother leaving her with the subjective
probability of 25% of having a sick baby. The question now becomes this: what was the true level
of knowledge of the expert (as opposed to the mother)? Lets suppose that the probability of the
test showing a mutation in the right position when this position is in fact wild-type is 5% (a fairly
sloppy research scientist might be assumed to mislabel or otherwise mix up 1 test tube in 20,
sequencing error-rate must be much lower). Lets further suppose that the probability of the test
outcome being “wild-type” when the mother is in fact a mutation carrier is also 5%.
Using the Bayes rule we can calculate that the expert should now believe with 95% certainty that
the mother is a carrier.
If the expert believed that only 1% error-rate applies, then the level of his belief should rise to
99%.
The mother may know very little about genetics but this is surely not a valid reason to deprive
her of the chance of interpreting the statement: „it is over 95% probable that your baby boy will
have a fifty-fyfty chance of having the disease“? Or put differently: would it be a good idea to
wait several months in order to be able instead to say: „it is over 99,9% probable that your baby
boy will have a 50:50 chance of being sick“? It seems doubtful to me that the difference between
95% and 99,9% would be enough to change the mother‘s behaviour.
Morgan Price
23/02/2012 at 17:05
I’m all for barcoding samples, but does it really benefit research subjects to use a licensed
phlebotomist? To withhold diagnoses that are high-confidence, although not certain, because no
gene diagnostic test is licensed? To withhold a diagnosis for months because the subject does
not have insurance coverage for genetic counseling? It all seems incredibly paternalistic.
I’m also confused about reagent tracking. Assuming that most of the relevant data is from
second-generation sequencing, how will reagant tracking prevent errors in diagnosis? It doesn’t
sound very plausible — is there something I’m missing?
Gholson Lyon
24/02/2012 at 00:57
I just spent the past three days attending this molecular diagnostics conference, attended by
many specialists in the world of gene diagnostic testing http://www.triconference.com/. One
thing I confirmed for myself is that there is extreme variability in the turnaround time for various
“CLIA-certified” gene tests, and some organizations claim to be able to develop such tests
quickly and effectively in a matter of weeks. This was certainly not the case for me with the very
reputable diagnostic laboratory that I approached, as it took 6 months to develop and make
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available a single Sanger-sequencing based gene test for NAA10, for MANY reasons, including
financial reasons in terms of getting them to commit the resources necessary to develop the test
and officially offer it with sign-off by board-certified medical geneticists.
In terms of the above reader comment, medicine has always been very paternalistic, although
one purpose of my commentary is to empower patients and consumers by making it possible for
them to obtain a clinical-grade genome, at their request. Currently, any patient is allowed to
request a copy of their medical record, including laboratory test results. I have done this myself,
so I have copies of results from my electrolytes, cell counts and liver function tests. Likewise, if
someone sequenced my genome, I would like to be able to receive a copy of my genome,
including raw data, on a small terabyte hard drive, so that I can share it with whomever I choose
for further analysis. I am a participant in the Personal Genome Project, based out of Boston, so I
hope to receive back my genome, if and when they sequence me. But, we have rules and
regulations to maintain decent standards AND to impede quacks and other unethical types
“peddling” shoddy or fraudulent products. I am therefore calling for proper clinical standards to
be applied to the sequencing of the first exome and/genome from each live human being, so
that so that such exomes and genomes really can be the same as a “lab test” returned to the
patient or research participant. Right now, in the current situation, most genomes being
sequenced do NOT meet the criteria in place for laboratory tests.
To reinforce the above point, given the fact that some research (see Retraction Watch website) is
either not reproducible, poorly done, ill-conceived or even outright fraudulent, the critical
current issue relating to the “return of results” is to ensure that any exome or genome
sequencing of human beings is performed in an appropriate CLIA-certified (or equivalent) clinical
environment, with rigorous standards in place, including for sample collection. It is only then that
clinicians will be able to return results in any sort of meaningful quantity to research participants,
given that it is currently incredibly tedious and bureaucratic to develop one-by-one CLIA-
certified gene-based tests to validate mutations.
One cliffhanger is that our health care system, at least in America, is so badly broken that 8
months have gone by and the doctors for one of my research subjects, in which I discovered the
unrelated finding explaining his idiopathic hemolytic anemia (see my Discovery Medicine paper),
have still not ordered a CLIA-certified test for the mutations in PKLR causing this person’s
anemia. Apparently, this gene test is officially available only in Germany and the Netherlands, as
per the doctor’s office, and they don’t have the time to track down any company in America
willing to develop the test. It will likely also be difficult (as per usual) to get approval from
insurance to reimburse the cost of the test. So, he still doesn’t know that he is a carrier for these
mutations, even though he is likely going to get married and have kids soon. To me, it is
absolutely crazy that our health care system is unable and/or unwilling to invest enough money
and time in genetics testing, counseling and prevention. This is one of many reasons that I am
requesting that the first exome and whole genome sequencing in each human should be
completed in a CLIA-certified clinical environment, so that researchers can return such
information to participants and so they don’t have to face or go through what I am still dealing
with. Plus, I imagine many lawsuits will occur once research participants start passing on
mutations that were uncovered in research studies but not relayed back to the research
participants. Some researchers just tell me that I should give back my research results to these
participants, but that is BREAKING THE LAW, given that all clinical genetic testing in America is
regulated under CLIA, and my results were NOT generated in a CLIA environment. I am trying to
do the right thing here, including publicizing these major problems with the way in which current
exomes and genomes are being sequenced, at least in America.
Morgan Price
24/02/2012 at 16:20
“Some researchers just tell me that I should give back my research results to these participants,
but that is BREAKING THE LAW” — I sympathize. I hope your story will push the FDA to reform
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some of these rules.
Gholson Lyon
27/02/2012 at 15:29
Just FYI, this was also covered over the weekend here:
http://www.sltrib.com/sltrib/news/53503970-78/research-family-lyon-born.html.csp?page=1
Marie Godfrey
29/02/2012 at 05:47
I am probably not as up-to-date as I used to be when writing a blog on genetic testing, but–at
the time–CLIA certification was for quality of laboratories and testing and had no specific genetic
testing standards. For example, there was no requirement that a “gene” for condition X be
proven to cause condition X and certainly nothing to say that a specific DNA sequence be
matched to a specific condition. Many genetic testing laboratories available over the Internet may
advertise their CLIA-certification, but that doesn’t guarantee that their genetic testing is accurate
or correct.
Gholson Lyon
03/03/2012 at 10:35
To address the comment from Marie, the point is to have minimal clinical standards in place for
the first germline genome from each human, so that the genomic data can be returned to the
participants. There is simply a need in human genetics to re-establish the researcher-participant
contract, which will certainly be enabled by the return of results. An easy way to return results
has already been demonstrated by 23andMe, with their very useful interface, which could easily
be adopted for the delivery of whole genome data back to participants, as long as the sample
collection and sequencing is performed in a CLIA-certified manner in America. This is a much
more distributive model, whereby research participants really do participate in the analysis of
their genomes, and it relieves researchers of the burden of having to “return results all at once”,
as it is much easier to analyze and re-analyze the clinical genomes, as knowledge expands. The
bottom line is that clinical whole genome sequencing is coming very quickly, so I anticipate that
this will sort itself out as more people realize just how important it is to return results to
participants, particularly those results of high medical impact within particular family structures.
This is in the same vein of thought as the concept of “Clan Genomics” articulated in Cell. 2011
Sep 30;147(1):32-43. Clan genomics and the complex architecture of human disease. Lupski JR,
Belmont JW, Boerwinkle E, Gibbs RA.
Just as an aside, if one does a Pubmed search for “clan genomics”, the only other paper of
relevance is this below paper, which is also very interesting:
Proc Natl Acad Sci U S A. 2010 Jan 26;107 Suppl 1:1779-86. Epub 2009 Sep 23. Evolution in
health and medicine Sackler colloquium: Consanguinity, human evolution, and complex diseases.
Bittles AH, Black ML.
Gholson Lyon
09/03/2012 at 22:50
I am just cross-posting my response to a Letter to the Editor that appeared in Nature yesterday. I
posted this same thing to the Nature website, but I want to put it here as well. Here you go:
However, I would just point out here that I am only asking for the INITIAL germline genome for
each human to be sequenced with appropriate clinical standards, so that each human who is
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sequenced can have their genome given back to them and hopefully linked to their medical
record, with their consent. Whole Genome Sequencing is a disruptive technology that can finally
help bring forth individualized medicine, as discussed in Eric Topol’s new book, The Creative
Destruction of Medicine, but this may only come from consumers, rather than the biomedical
research complex.
The sequencing and return of genomic data can go a long way toward implementing some carrier
screening for highly penetrant mutations, some of which can have relative risks of 7,500-
10,000x (acknowledgement here to following reference: Genet Med. 2012 Feb 16. doi:
10.1038/gim.2011.78. [Epub ahead of print] Opportunities and challenges for the integration of
massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project.
Biesecker LG.)).
The bottom line is that potentially many humans will carry such mutations, and it would be
enormously useful to catalog human genetic variation by actually sequencing and returning
whole genomes to humans in a clinical setting. A further benefit could be to centralize these
genomes in one database, so that it is MUCH easier to calculate penetrance of disease with
certain mutations. As I say, this is a disruptive technology, particularly if done to scale in
centralized facilities that are specialized for whole genome sequencing, and the time is fast
approaching when this can and should be done in at least developed countries.
Also, the Retraction Watch website documents what I believe is just the “tip of the iceberg” in
terms of research that is outright wrong and therefore a complete waste of money, and I would
argue that this is because there are no set or required standards for good high-quality research.
Requiring that all initial germline genomes be performed at the level of Good Clinical Practice
seems like a great idea to me, so that we can at least get high-quality genomes going forward.
Right now, many sequencing centers are sequencing thousands of germline exomes and
genomes, but not with any clinical standards in place, so all of that data cannot be returned to
research participants, plus the raw sequencing data are not being freely shared, at least not
readily. To me, that is a huge waste of money, particularly given that people who take the time
to donate their blood and saliva typically want to hear about their own results.
Of course, we can argue about when exactly will be a good time to sequence everyone’s genome
in a clinical setting, but I sure hope that in 20-50 years time, every infant born (at least in
industrialized countries) will have their genome sequenced, so that preventive and therapeutic
services can finally be offered on a more individual level. I am just trying to do my little bit to
move that time closer to 20 years, in contrast to 50 years! I would recommend people read Eric
Topol’s book, along with Michael Nielsen’s book on Reinventing Discovery: The New Era of
Networked Science. I have attached some other references in my posting at Genomes Unzipped.
Since the publication of this commentary, I have had MANY people tell me that this is indeed a
major problem that needs to be addressed, given the therapeutic misconception that many
people have when they enroll in a human genetics study, no matter what they are told. I am
attempting to head off a huge crisis that might occur when and if many research subjects are
not informed about highly penetrant mutations discovered in their exomes and genomes by
researchers. I would highly recommend people read the story of one patient and now patient
advocate Rebecca Fisher, as per below:
A closer look revisited: are we subjects or are we donors? Rebecca Fisher, MLIS, Genetics in
Medicine, advance online publication 23 February 2012. doi:10.1038/gim.2012.6.
s Jett
02/07/2012 at 18:06
Truth and information should be put way above politics and allow
a person to make their decisions based on KNOWLEDGE. It’s not fair
for the researchers to play god or withhold information they have
discovered from a potential parent who may have to deal w/ the possibility of passing this gene
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forward. Be honest, screw politics
Frank
19/12/2012 at 05:59
I think what’s missing from this discussion is the need for clinical validation of genetic markers.
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